One of the hallmarks of pediatric ALL is the presence of subtype-defining chromosomal translocations that cause gene fusions involving master regulators of hematopoietic development. These initiating lesions often cooperate with specific somatic aberrations including monoallelic deletions of B-cell developmental genes, such as *PAX5, IKZF1* and *EBF1*^[@R1]^. Other cooperative liaisons are represented by trisomy 21q22 with *CRLF2* activation^[@R2]-[@R4]^ or near-haploid ALL with activation of receptor tyrosine kinase or RAS signaling^[@R5]^. RAS pathway mutations appear in high-risk ALL, but are often lost with disease progression, suggesting the involvement of additional tumorigenic factors^[@R6],[@R7]^. The patterns of recurrent genomic alterations need to be better understood, because apart from tyrosine kinase inhibitor-supplemented treatment of *BCR-ABL1*-positive ALL, the only proven successful first-line treatment strategies for high-risk ALL are chemotherapy intensification and early allogeneic hematopoietic stem cell transplantation^[@R8]^.

The translocation t(1;19)^[@R9]^ that fuses the transcriptional activation domain of the B cell developmental transcription factor TCF3 to the DNA-binding domain of PBX1 occurs in about 5-10% of precursor B cell (pre-B) ALL patients and is associated with a median five-year event-free survival probability of 78-85%^[@R10]^. In contrast, the translocation t(17;19)(q22;p13), resulting in the fusion gene *TCF3-HLF*, defines a rare subtype of ALL (\<1% of pediatric ALL) that is typically associated with relapse and death within two years from diagnosis^[@R11],[@R12]^. Both translocations disrupt one allele of *TCF3,* which drives the B-cell differentiation program upstream of the transcription factor *PAX5*^[@R13]^. As an initiating event, expression of *TCF3-HLF* leads to transcriptional reprogramming in pre-leukemic cells. Possible direct targets of TCF3-HLF include the transcription factor gene *LMO2*, which is implicated in initiation of T ALL^[@R14],[@R15]^, and the transcriptional repressor *SNAI1* (*SLUG*), which regulates embryonic development and apoptosis^[@R16],[@R17]^. Further targets were proposed, including *BCL2*^[@R14]^. The *TCF3-HLF* fusion likely requires additional events to cause leukemia, because *TCF3-HLF* transgenic and knock-in mice did not recapitulate the human phenotype^[@R18],[@R19]^.

Here, we report that the genomic and transcriptomic landscape of *TCF3-HLF*-positive ALL differs markedly from *TCF3-PBX1*-positive ALL. The *TCF3-HLF* fusion likely occurs in B lymphoid progenitors in the context of *PAX5* haploinsufficiency and is associated with transcriptional reprogramming towards an immature, hybrid hematopoietic state. Drug response profiling in patient-derived xenografts, which maintained the genomic and global transcriptome landscapes of the corresponding primary leukemic samples, identified resistance patterns to drugs commonly used for the treatment of *TCF3-HLF*-positive patients. A general trait of *TCF3-HLF*-positive ALL in our study is extreme sensitivity towards the BCL2-specific inhibitor ABT-199 (venetoclax), indicating new therapeutic options for this fatal ALL subtype.

RESULTS {#S1}
=======

Next generation sequencing (NGS) analysis integrating short and large insert size paired-end whole genome (WGS), whole exome (WES) and transcriptome (RNAseq) sequencing was applied to a discovery cohort consisting of five diagnostic pre-treatment samples of *TCF3-PBX1*-positive (samples 1a-5a) and *TCF3-HLF*-positive (samples 6a-9a and 11a) ALL, respectively. Matched bone marrow samples collected after induction treatment for minimal residual disease evaluation (MRD, maximum leukemic cell load ≤10^−3^; samples 1b-9b and 11b) were used as non-tumor controls ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Additional DNA samples from seven *TCF3-HLF*-positive (diagnostic samples 10a, 12a, 13a, 14a, 15a, 16a, 17a, remission samples 10b, 12b, 13b) and 24 *TCF3-PBX1*-positive cases were used for validation **(**[Supplementary Tables 2](#SD2){ref-type="supplementary-material"} and [3](#SD2){ref-type="supplementary-material"}). In most cases *TCF3-HLF*-positive ALL responded to induction chemotherapy, but remained MRD positive. Nine children included in this study died due to disease progression and treatment-related toxicities within 2 years on average and only one patient is in remission after a short follow-up time, reflecting the dismal prognosis of *TCF3-HLF*-positive ALL.

TCF3 breakpoints suggest a committed lymphoid cell of origin {#S2}
------------------------------------------------------------

Consistent with previous reports^[@R20],[@R21]^, all *TCF3* translocation breakpoints were restricted to three hotspot regions ([Fig. 1a](#F1){ref-type="fig"} and 1b and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Those were associated with small non-template nucleotide insertions indicative of terminal deoxynucleotide transferase (TdT) activity characteristic of an early B cell stage ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}). In *TCF3*, the breakpoints clustered in close proximity to CpG elements in the absence of classical RAG consensus sequence sites ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), which is a characteristic feature of translocations that occur in lymphoid progenitors at the pro-/pre-B stage. This may represent illegitimate RAG-mediated recombination at cryptic sites, possibly in the context of deaminated CpG nucleotides as proposed for *TCF3-PBX1* translocations^[@R22]^. Consistent with the idea that *TCF3-HLF* may occur at a lymphoid-committed rather than a pluripotent progenitor stage, we detected this translocation only in sorted pre-B cell populations containing leukemic cells but neither in stem cells nor in myeloid progenitor cells ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}).

TCF3-HLF ALL and impaired pro- to pre-B cell transition {#S3}
-------------------------------------------------------

Pre-B cell ALL is frequently associated with somatic copy number alterations affecting B cell developmental genes. *PAX5* deletions are generally observed in 13% of ALL cases and in up to 28% of high-risk ALL^[@R23]^. We observed enrichment for monoallelic *PAX5* deletions in *TCF3-HLF*-positive ALL reaching 67% of the cases ([Fig. 1c](#F1){ref-type="fig"}, [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Illegitimate RAG-mediated recombination appears to be implicated in the generation of such events in *TCF3-HLF*-positive ALL given the close proximity to RSS motifs ([Supplementary Table 5](#SD3){ref-type="supplementary-material"}). In most samples without *PAX5* deletion, we identified hemi- and homozygous deletions of *VPREB1,* a component of the surrogate light chain of the pre-B cell receptor ([Fig. 1c](#F1){ref-type="fig"}, [Supplementary Table 6](#SD3){ref-type="supplementary-material"}) independent of the lambda light chain locus. *VPREB1* deletions in pediatric ALL result in failure to form a viable surrogate light chain in the pre-B cell receptor, an event associated with lower overall survival^[@R24]^. In addition, we detected *BTG1* gene deletions in three out of eight *TCF3-HLF*-positive cases without *PAX5* deletions ([Supplementary Fig. 3a and 3b](#SD1){ref-type="supplementary-material"}). *BTG1* deletions occur frequently in ALL positive for *ETV6-RUNX1* (19%) or *BCR-ABL1* (26%) and may confer a proliferative advantage^[@R25]^. In contrast, no deletion, but only a single *PAX5* nonsense mutation could be detected in 29 *TCF3-PBX1*-positive cases ([Fig. 1](#F1){ref-type="fig"} and [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Our results indicate that cooperative genetic events affecting genes regulating the pro- to pre-B cell transition, in particular *PAX5, BTG1 and VPREB1,* but not *IKZF1,* are selected in *TCF3-HLF*-translocated cells. Other deleted genes associated with pre-B cell ALL^[@R26]^ were *JAK2* and *CDKN2A/B* (patient 7a and 11a) and transcriptional regulators such as *ERG, NCOR1*, *TOX*, *BACH2*, *BCL7C*, *MLLT3*, *SMARCA2*, and *MAFK* ([Fig. 1c](#F1){ref-type="fig"}).

Recurrent RAS pathway mutations in *TCF3-HLF* ALL {#S4}
-------------------------------------------------

We identified only a few additional somatic alterations affecting protein-coding sequences in both *TCF3-PBX1*- and *TCF3-HLF*-positive ALL ([Fig. 1c](#F1){ref-type="fig"}, [Supplementary Tables 6](#SD3){ref-type="supplementary-material"} and [7](#SD3){ref-type="supplementary-material"}), involving among others, genes associated with pre-B cell ALL^[@R26]^ (*TCF3*, *PAX5*, *LEF1)* and transcriptional and chromatin regulation (*ZNF263*, *MLL2*, *HIST1H3A*, *C6orf89*). We observed a prominent association of *TCF3-HLF*-positive ALL with activating mutations in RAS signaling pathway genes (*NRAS*, *KRAS*, and *PTPN11)*, detectable in four out of five discovery cases ([Fig. 1c](#F1){ref-type="fig"}) and in three out of five additional *TCF3-HLF*-positive validation samples (*PTPN11* and *SPHK1)* ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). No RAS pathway mutations were identified in the *TCF3-PBX1*-positive discovery cohort and only one oncogenic *NRAS* mutation was detected in the 24 *TCF3-PBX1*-positive validation cases ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}). *NRAS* and *KRAS* mutations were generally detected in subclones ([Supplementary Table 7](#SD3){ref-type="supplementary-material"}). Interestingly, we discovered a novel fusion gene, *KHDRBS1-LCK*, due to an interstitial chromosomal deletion in one *TCF3-HLF*-positive sample (6a), triggering the overexpression of the *LCK* tyrosine kinase ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). This was also present in three out of 74 randomly selected ALL samples, demonstrating that *KHDRBS1-LCK* fusion is recurrent in ALL ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). LCK is a drug target in RAS-dependent cancer cells which have higher *LCK* expression^[@R27]^, suggesting a possible interplay with RAS-related signaling networks in *TCF3-HLF*-positive ALL. Oncogenic activation of LCK associated with t(1;7)(p34;q34) translocation was reported in the T cell leukemia cell line HSB2^[@R28]^. Our data indicate a frequent association of proliferation-driving mutations in *TCF3-HLF*-positive ALL in the context of stalled B cell differentiation.

Mutations affecting the second *TCF3* allele in *TCF3-HLF* ALL {#S5}
--------------------------------------------------------------

We identified a mutation in the basic helix-loop-helix region of *TCF3* (p.Asp561Val, D561V, [Fig. 1c and 1d](#F1){ref-type="fig"}) affecting the non-translocated chromosome in one *TCF3-HLF*-positive case (8a). Mutations at this position were reported in sporadic Burkitt lymphoma^[@R29]^ and may reduce binding to its negative regulator ID3^[@R29]^. Based on available crystal structure data, p.Asp561Glu may affect the interaction of *TCF3* with the transcription factor SCL (also known as TAL1; [Fig. 1d](#F1){ref-type="fig"}), possibly altering *TCF3* protein complexes. A second *TCF3* mutation (p.Ser467Gly) was detected in another *TCF3-HLF*-positive case (13a, [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). The functional consequences of this mutation are currently unclear. Interestingly, we could not detected any somatic mutations in *TCF3* by targeted sequencing of 1,033 unselected ALL patients from the European multicenter trial AIEOP-BFM ALL 2000, suggesting a specific association with *TCF3-HLF*-positive ALL ([Supplementary Table 8](#SD2){ref-type="supplementary-material"}). Thus, deregulation of normal *TCF3* function may also contribute to *TCF3-HLF*-positive ALL. Corroborating our findings, a recent study included a single *TCF3-HLF* case, as part of a cohort comparing diagnostic and relapse ALL samples, which showed a *PAX5* deletion and two mutations in *TCF3* (p.His460Tyr, p.Gly470fs), all of which were conserved at relapse^[@R30]^. Besides, the relapse sample featured a *VPREB1* deletion as well as a shift in subclonal mutations in *NRAS* (p.Gly12Asp and p.Gly12Val), reinforcing the idea of cooperative effects between *TCF3-HLF* and alteration of *PAX5 and VPREB1* gene dosage. Taken together, seven out of eleven *TCF3-HLF* cases were hemizygous for *PAX5*, whereas five samples featured *VPREB1* deletions (summarized in [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}).

Reprogramming towards a more immature state in *TCF3-HLF* ALL {#S6}
-------------------------------------------------------------

Consistent with the occurrence of *TCF3-HLF* and *TCF3-PBX1* translocations in lymphoid precursors, both leukemia subtypes shared a gene expression signature of B-lymphoid cells (including *PAX5, BLK, CD19*, *CD22, CD79B*, *TCF3*, *EBF1*, *VPREB1*, *RAG1*, *ROR1*, *BLNK*, and *DNTT*) ([Supplementary Tables 9](#SD3){ref-type="supplementary-material"} and [10](#SD3){ref-type="supplementary-material"}), but differential expression of 401 genes (false discovery rate ≤ 0.001) strongly distinguished the two *TCF3*-translocated subtypes ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Tables 11](#SD3){ref-type="supplementary-material"} and [12](#SD3){ref-type="supplementary-material"}). *In silico* prediction of transcription factor binding sites (TFBS) in the corresponding promoter regions revealed significant enrichment for PBX and HLF binding motifs associated with *TCF3-PBX1*- and *TCF3-HLF* gene signatures, respectively ([Supplementary Tables 13](#SD1){ref-type="supplementary-material"} and [14](#SD3){ref-type="supplementary-material"}**)**. Further, *PBX1* and *HLF* were the only transcription factors among those with enriched binding motifs which were significantly differentially expressed between the two ALL subtypes and between leukemia and remissions. The chimeric *HLF* transcript was strongly induced in *TCF3-HLF*, but no wild-type *HLF* expression could be detected. We predicted 39 potential HLF targets, including the known target *SNAI2* (*SLUG*)^[@R16]^, *GPC4* and *BMP3* involved in stem cell proliferation, which showed induced expression in *TCF3-HLF* samples ([Supplementary Table 15](#SD3){ref-type="supplementary-material"}). Other potential *TCF3-HLF* targets that regulate developmental programs and cell survival, such as *LMO2*^[@R14]^ and *BCL2*^[@R14]^, were not predicted. However, their expression was increased in *TCF3-HLF*-positive ALL.

Gene set enrichment analysis (GSEA) using gene sets from sorted human hematopoietic stem cells (HSC) and early progenitor populations^[@R31]^ as well as curated oncogenic (C6) and human immunologic (C7) signatures from MsigDB^[@R32]^ revealed an enrichment for stem cell and myeloid signatures in *TCF3-HLF*-positive ALL. In contrast, lymphoid features were more prominent in *TCF3-PBX1*-positive ALL ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Table 16](#SD3){ref-type="supplementary-material"}). The HSC signature l^[@R31]^ ranked among the top gene sets enriched in *TCF3-HLF*-positive ALL ([Fig. 2c](#F2){ref-type="fig"}, [Supplementary Table 17](#SD3){ref-type="supplementary-material"}). We obtained similar results using an independent method based on text mining annotations ([Fig. 2d](#F2){ref-type="fig"}, [Supplementary Tables 18](#SD3){ref-type="supplementary-material"} and [19](#SD3){ref-type="supplementary-material"}). High expression of the stem cell marker *LGR5*^[@R33]^ was consistently detected in *TCF3-HLF*-positive ALL suggesting a reactivation of immature features shared with other stem cell populations. Consistent with previous reports, the myeloid marker CD33 was expressed in *TCF3-HLF*-positive blasts, which provides a target for antibody-directed therapy^[@R12],[@R34]^. Other differentially expressed genes, such as *BMP2*^[@R35]^, could present additional therapeutic targets.

Our results are consistent with a model in which *TCF3-HLF* arises in lymphoid cells and promotes transcriptional reprogramming towards a hybrid hematopoietic state. Features of mesenchyme-derived tissues were also detected in *TCF3-HLF*-positive ALL, which may indicate a profound cellular reprogramming towards a drug-resistant state.

Mutation profiles of *TCF3-HLF* ALL are conserved in xenografts {#S7}
---------------------------------------------------------------

We generated leukemia xenografts in immunodeficient NOD/SCID/IL2rγ^null^ (NSG) mice for all cases included in this study ([Supplementary Table 20](#SD3){ref-type="supplementary-material"})^[@R36],[@R37]^. We also established for the first time to our knowledge leukemia xenografts from follow-up samples with MRD, some with less than 0.1% ALL cells after induction chemotherapy ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Tables 1](#SD3){ref-type="supplementary-material"} and [20](#SD3){ref-type="supplementary-material"}). Leukemia and MRD engraftment was rapid with conserved and predictable kinetics for xenografts derived from the same patient ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}), suggesting that no major adaptation to the mouse microenvironment was needed for proliferation. Most SNVs and intrachromosomal deletions that were present at diagnosis were conserved in the corresponding xenografts ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Table 7](#SD3){ref-type="supplementary-material"}). Only deletions detected in the relapse sample 11c were not conserved in the corresponding xenografts and a deletion in *BTG1* emerged in one MRD-derived sample (patient 7b, [Supplementary Fig. 3c and 3d](#SD1){ref-type="supplementary-material"}). A few mutations were lost in MRD or relapse xenograft samples, including *GNB1* and *DDX3X* indicating that these are probably dispensable or may cause drug sensitivity. Mutations in the RAS pathway were largely maintained in xenografts. However, the *NRAS* mutation p.Gln61His identified in the primary MRD sample 7b was not detected in the corresponding xenograft. Interestingly, a heterozygous damaging mutation in *KRAS* (p.Lys147Glu) associated with Noonan syndrome^[@R38]^ emerged instead. In patient 9a we identified two subclones displaying either a *KRAS* (p.Gly13Asp) or an *NRAS* (p.Gly12Ser) mutation. The corresponding xenograft retained only the *KRAS* mutated sub-clone. Thus, maintenance and acquisition of RAS pathway mutations in xenografts support the notion that they occur later during selection at a multiclonal level and confer a selective advantage in *TCF3-HLF*-positive ALL. No other SNVs emerged *de novo* in the xenografts. In summary, the molecular characteristics of both leukemia subtypes were largely conserved in the xenografts, confirming the validity of this model.

*TCF3-HLF*-associated gene expression is maintained in xenografts {#S8}
-----------------------------------------------------------------

Hierarchical clustering based on the gene signature specifying the two leukemia subtypes showed that the expression profile and the subtype-specificity of the primary leukemia were maintained in the xenografts ([Fig. 4](#F4){ref-type="fig"}). The genes most significantly upregulated in matched patient and xenograft samples from *TCF3-HLF*-positive leukemia specified stem cell features ([Supplementary Table 21](#SD3){ref-type="supplementary-material"} and [22](#SD3){ref-type="supplementary-material"}). Similar to patient samples, features of mesenchyme-derived tissues were also detected in xenografts derived from *TCF3-HLF*-positive ALL. Strikingly, *TCF3-HLF*-positive leukemias and xenografts displayed systematic down-regulation of *PAX5* expression to halved levels. Though mono-allelic deletions of *PAX5* were a prominent feature of *TCF3-HLF*-positive ALL, reduced expression was also seen in diploid cases, hinting at alternative molecular mechanisms. The recapitulation of this pattern in the xenograft samples enforces the notion that *TCF3-HLF*-positive leukemia emerges in a specific cellular context with reduced *PAX5* expression ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). The essential molecular features of *TCF3-HLF*-positive samples were maintained in xenografts, providing a useful model of this disease.

Drug activity profiling of *TCF3-HLF* and *TCF3-PBX1* ALL {#S9}
---------------------------------------------------------

To determine drug sensitivity and resistance profiles, we established ALL co-cultures on human mesenchymal stromal cells (MSC) under serum-free conditions.^[@R39]^ Both subtypes depend on stroma for survival ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). *TCF3-PBX1*-positive ALL had a higher proportion of cells in S-phase than *TCF3-HLF*-positive ALL on such cultures, reflecting consistent biological differences. By screening 98 bioactive agents, including many agents in clinical development ([Supplementary Table 23](#SD3){ref-type="supplementary-material"}), on an automated-microscopy-based platform, we unambiguously discriminated the two translocations based on their drug sensitivity profiles, using either single (logIC~50~, [Fig. 5a](#F5){ref-type="fig"}, [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}) or multiple response parameters (logIC~50~, logEC~90~, logEC~50~ and AUC, [Fig. 5b](#F5){ref-type="fig"} and [Supplementary Table 24](#SD3){ref-type="supplementary-material"}). To capture informative differences, we compared the responses of xenografts derived from *TCF3-HLF*-positive ALL to xenografts derived from other high-risk pre-B and T ALL patients on the same platform ([Fig. 5c](#F5){ref-type="fig"} and [Supplementary Table 25](#SD3){ref-type="supplementary-material"}). This provided information about the activity range of each drug on the respective ALL subtype. *TCF3-HLF*-positive cases were consistently more resistant to various drugs from the same class, including nucleotide analogs (e.g. cytarabine), mitotic spindle inhibitors (e.g. vincristine), polo-like and aurora kinase inhibitors. Given the importance of cytarabine and vincristine in standard ALL therapy, the implications of these observations need to be further explored. *TCF3-HLF*-positive ALL was very resistant to dasatinib in this assay, while *TCF3-PBX1*-positive ALL responded well. This partly challenges a recent report,^[@R40]^ which proposed dasatinib as an alternative for the treatment of these leukemias based on strong *in vitro* activity in one *TCF3-HLF*- and ten *TCF3-PBX1*-positive primary ALL samples. However, *in vivo* studies will be required to verify these differences in drug response, as differences in cell cycle activity may influence the pattern of response *in vitro*.

*TCF3-HLF*-positive ALL were sensitive to glucocorticoids (prednisone, dexamethasone) and to other drugs that could be relevant for the treatment of resistant ALL, including mTOR inhibitors, anthracyclines, bortezomib, the HSP90 inhibitor AUY922, and panobinostat. However, in spite of the good response of patients with *TCF3-HLF*-positive leukemia to prednisone therapy and the observed responsiveness of *TCF3-HLF*-positive ALL cells to glucocorticoids and anthracyclines that are commonly used in ALL treatment, patients eventually will relapse. Our transcriptome data suggested that resistance to apoptosis due to high expression of the anti-apoptotic oncoprotein BCL2 might promote cancer cell survival and constitute a druggable target **(**[Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}**)**. *BCL2* is a putative transcriptional target of *TCF3-HLF*^[@R14]^. Of note, PAX5, commonly deleted in our cohort, normally represses *BCL2* transcription^[@R41]^.

*TCF3-HLF* ALL is extremely sensitive to the BCL2 antagonist venetoclax {#S10}
-----------------------------------------------------------------------

To assess the role of *BCL2* overexpression in *TCF3-HLF*-positive ALL and to provide preclinical evidence for therapeutic activity, we tested the BCL2-targeting drug venetoclax (ABT-199) in our xenograft model ([Fig. 5c](#F5){ref-type="fig"}). This BH3-mimetic compound is a highly specific small molecule inhibitor that competes with pro-apoptotic BCL2 family proteins for binding to BCL2 and shifts the balance of pro-death and pro-survival signals inside the cell in favor of cell death^[@R42]^. Venetoclax is in clinical development (phase II and III trials) for chronic lymphocytic leukemia and lymphoma, and holds promises for ALL and acute myeloid leukemia (AML).

*TCF3-HLF*-positive ALL samples were more sensitive to venetoclax than *TCF3-PBX1*-positives ([Fig. 6a](#F6){ref-type="fig"}), which correlated with higher *BCL2* transcript and protein expression levels ([Fig. 6b](#F6){ref-type="fig"}). A two-week treatment course of daily venetoclax administration delayed leukemia progression significantly in ALL xenografts from three different *TCF3-HLF*-positive cases ([Fig. 6c and 6d](#F6){ref-type="fig"}). Treatment of mice in the control arm that reached maximal leukemia burden resulted in very rapid reduction of the leukemic load ([Fig. 6e](#F6){ref-type="fig"}). Xenografts from MRD or relapse remained sensitive to venetoclax ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}). Profiling of primary cells from two additional cases with refractory ALL confirmed exquisite sensitivity to venetoclax ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}). Combined treatment of patient-derived xenografts from patients 6 to 11 with venetoclax and either vincristine or dexamethasone indicated a potentially synergistic effect in some of those patients ([Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}, [Supplementary Table 26](#SD3){ref-type="supplementary-material"}). Our data identify BCL2-dependency in *TCF3-HLF* ALL as a druggable target and illustrate how integration of drug response profiling and molecular genetic analyses can inform the development of innovative treatment strategies in patients with unmet therapeutic needs.

DISCUSSION {#S11}
==========

To our knowledge, long-term cure has never been achieved for patients with *TCF3-HLF*-positive ALL. Our study revealed a recurrent pattern of *TCF3-HLF* accompanied by abnormalities that affect transcriptional regulation of lymphoid development. We found frequent deletions of *PAX5* and *VPREB1* in association with *TCF3-HLF,* but deletions of Ikaros family members, which are commonly affected in ALL^[@R1],[@R23]^, were not detected. We also uncovered recurrent mutations of the transcription factor TCF3, which acts upstream of PAX5 in lymphoid development, potentially impairing structural interactions with other transcription cofactors^[@R29]^. *PAX5* expression was reduced by two-fold in all *TCF3-HLF*-positive cases, underscoring the possibility of an interaction between TCF3-HLF, TCF3 and PAX5. *PAX5* is required for B-lymphoid lineage commitment and maturation^[@R43]^ and frequently deleted in high-risk ALL with complex patterns of copy number abnormalities^[@R23]^. Similarly, deletions in *IKFZ1*, which is required for the development of B- and T-lymphoid lineages and has additional stem cell-like functions^[@R44]^, are detected both in high-risk *BCR-ABL1*-positive and -negative ALL and in the more favorable *ERG*-altered ALL subtype^[@R45]^, but never in *TCF3-HLF*-positive ALL. Focal deletions of *VPREB1* were also detected in *TCF3-HLF* ALL which may lead to a developmental arrest associated with lack of pre-B cell receptor formation and the resulting loss of negative feedback on RAG-mediated recombination^[@R46]^. *VPREB1* deletions were present at a similar frequency compared to other high-risk ALLs, such as *BCR-ABL1*-like and *BCR-ABL1*-positive ALL (approximately 30-40% of cases)^[@R47]^ or hypodiploid ALL (≈30%)^[@R24]^, associated with poorer overall survival in high-risk pre-B cell ALL patients^[@R24]^. However, specific ALL subtypes associated with good prognosis (e.g. *ETV6-RUNX1*-positive ALL) also present high frequencies of *VPREB1* deletions^[@R24]^, suggesting an important impact of the genomic context^[@R24]^. Thus, distinct patterns of association emerge that are likely to reflect important underlying biological mechanisms. Based on our results, we propose that a reduction of *PAX5* gene dosage constitutes a favorable context for the oncogenic activity of *TCF3-HLF*.

As observed for hypodiploid ALL^[@R5]^ and in subsets of *MLL*-rearranged ALL^[@R48]^, we identified mutations in *NRAS*, *KRAS* and *PTPN11* in *TCF3-HLF*-positive ALL. In our xenograft models we detected variable persistence of *NRAS* and a switch to *KRAS* mutations, indicating that RAS mutations are multiclonal and might not be strictly required for disease progression in *TCF3-HLF*-positive ALL. Indeed, mutations in the RAS pathway are enriched at relapse in ALL^[@R7],[@R30],[@R48]^, but mostly in a subclonal pattern with losses or switches in *NRAS* and *KRAS* from diagnosis to relapse. These represent secondary events, possibly compensating functional effects of the initiating events. Mutations in the RAS pathway might not represent optimal therapeutic targets, given their volatility and the potential to select for slower proliferating, more resistant subclones. The *TCF3-HLF* gene expression signature, enriched for components of stem cell and myelomonocytic stages, was very similar among leukemias and maintained in xenografts, specifying additional, novel markers associated with stem cell function, such as *LGR5*, which marks epithelial stem cells^[@R49]^ and embryonic and fetal hematopoietic progenitor cells in mice^[@R50]^. Thus, in analogy to experimental induction of pluripotent stem cells^[@R51],[@R52]^, *TCF3-HLF* likely induces a whole set of factors that carry out reprogramming and leukemic transformation in the context of low *PAX5* expression. Deletion of *PAX5* in early B cell progenitors induced dedifferentiation to a state with myeloid and T cell potential^[@R43],[@R53]^. Moreover, rescue with low expression levels of PAX5 in knock-out mice generates a stalled biphenotypic B-lymphoid/myeloid state^[@R54]^. Together with an activating mutation in *STAT5*, *PAX5* haploinsufficiency initiates ALL in mice^[@R41]^. Based on these data, we propose that the initiating *TCF3-HLF* fusion results in severe transcriptional reprogramming with dedifferentiation. The favorable context for transformation is secured in second line through additional lesions in early B cell differentiation genes including *TCF3* and *PAX5*.

A central question remains pertaining to the cell of origin in different ALL subtypes. Our study provides significant clues that should be further addressed using disease models. The molecular analysis of the *TCF3-HLF* and *TCF3-PBX1* fusion gene breakpoints indicated that the *TCF3-HLF*, like the *TCF-PBX1* translocation, originates in cells already committed to lymphoid differentiation. Furthermore, the associated somatic structural variants were found to be RAG-mediated, which is comparable to patterns identified recently in *ETV6-RUNX1*-positive ALL, the most frequent pre-B cell ALL subtype, which is consistent with expression of RAG in *TCF3-HLF*-positive ALL^[@R55]^. We favor the hypothesis that the *TCF3-HLF* translocation occurs in a B cell progenitor and that the specific lineage context is constrained further in a restricted developmental stage by additional mutations. The detection of *TCF3-HLF* being restricted to leukemic cells supports this idea, although initiation in a more immature compartment cannot be formally excluded.

The molecular landscapes of *TCF3-HLF*-positive ALL were largely conserved in xenografts, providing a valuable, well characterized, model for preclinical testing. Drug activity profiling revealed that *TCF3-HLF*-positive cases were more resistant to several standard ALL drugs, such as nucleotide analogues (e.g. cytarabin) and mitotic spindle inhibitors (e.g. vincristine). Activity was detected for other relevant drug classes, such as mTOR inhibitors, the proteasome inhibitor bortezomib, the HSP90 inhibitor AUY922, and the HDAC inhibitor panobinostat. The BCL2 inhibitor venetoclax (ABT-199)^[@R42]^ was highly active in all *TCF3-HLF*-positive cases analyzed, which we confirmed using primary ALL cells from two additional cases with refractory disease. These results refine data obtained using the broader spectrum BH3-mimetic ABT-737 in *TCF3-HLF*-positive cell lines^[@R14]^. Given the activity of venetoclax also in other ALL subsets including immature T ALL (^[@R56],[@R57]^ and own unpublished data) and the lack of on-target thrombocytopenia caused by ABT-737, venetoclax should be explored for experimental therapy in refractory ALL in selected cases based on such functional data. Thus integrated genomic and functional analyses of *TCF3-HLF*-positive ALL provide novel insight into the molecular context and associated components and offer unprecedented possibilities to investigate new agents for the treatment of these children who currently lack effective therapeutic options.

ONLINE METHODS {#S13}
==============

Study individuals and sample selection {#S14}
--------------------------------------

Samples and associated clinical information from patients included in sequencing and validation analyses were collected from different countries within the International BFM-Study Group (IBFM-SG). All patients were enrolled in multicenter trials on treatment of pediatric ALL conducted by individual member groups of the I-BFM-SG: the AIEOP-BFM study group (Austria, Germany, Italy, Switzerland), the FRALLE study group (France), and the United Kingdom (UK) National Cancer Research Institute (NCRI) Childhood Cancer and Leukaemia Group^[@R61],[@R62]^. All treatment trials were approved by the respective national institutional review boards and informed consent for the use of spare specimens for research was obtained from study individuals, parents or legal guardians. The specific research project reported here was approved by the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University, Kiel, Germany (vote D508/13). Depending on consent and availability of samples, all enrolled patients positive for the rare *TCF3-HLF* gene fusion were included. These patients were matched with *TCF3-PBX1*-positive patients. Download of sequencing data is available from the public POPGEN repository (Christian-Albrechts-University, Kiel) upon written request accompanied by a positive internal review board vote for research addressing leukemia-related questions. Data transfer can proceed upon positive review and signing of a material transfer agreement.

Cell isolation and nucleic acid purification {#S15}
--------------------------------------------

Mononuclear cells (MNCs) were isolated by Ficoll-Paque gradient centrifugation (Pharmacia) from bone marrow or peripheral blood samples followed by extraction of nucleic acids according to standardized protocols using Qiagen DNA Blood Kits (Qiagen) for DNA and Qiagen RNeasy columns (Qiagen) for RNA. The quantity of nucleic acids was determined by spectrophotometry. DNA quality was assessed visually by inspection of agarose gel electrophoresis while RNA integrity was evaluated by using the Bioanalyzer 2100 (Agilent). Nucleic acids isolated from bone marrow aspirates collected in morphological remission served as individual germline surrogates/references.

Sequencing {#S16}
----------

### Whole genome sequencing {#S17}

For structural variants (SVs), Illumina v2 mate-pair libraries with 5 kbp insert size and 2 × 101 bp reads were prepared from 10 μg of DNA and sequenced on the Illumina HiSeq 2000 platform (Illumina) to obtain a physical coverage of 30x. For copy number alterations, breakpoints and short variants (SNVs, short indels), Illumina TruSeq paired-end libraries with 2 × 101 bp reads were prepared from 1 μg of DNA and sequenced on HiSeq 2000/2500 instruments to a coverage of 40x for reference samples and 80x for tumor samples.

### Whole exome sequencing {#S18}

For increasing the sensitivity of detecting short variants in coding regions, 1 μg of DNA each from the diagnostic leukemic and a corresponding remission sample of patients was used for whole exome sequencing. Whole exome capture employed a TruSeq enrichment kit (Illumina) and paired-end libraries with 2 × 101 bp reads on a HiSeq 2500 according to the manufacturer's protocol.

### Whole transcriptome sequencing {#S19}

Illumina TruSeq custom stranded paired-end libraries with 2 × 51 bp reads were prepared from 1 μg RNA using the Ribo-Zero Gold Kit (Epicentre) and sequenced on a HiSeq 2000 with a loading of one library per lane.

### Sanger sequencing validation {#S20}

Structural variant breakpoints from mate-pair genome sequencing and SNVs from exome sequencing were validated by Sanger sequencing.

### Targeted sequencing of TCF3 and RAS pathway candidate genes {#S21}

*TCF3* binding domain (E47 isoform, exon 18) mutations were screened for in 1033 ALL patients using Sanger sequencing. Primer sequences are listed in [Supplementary Table 27](#SD3){ref-type="supplementary-material"}. Sanger sequencing was also applied for validation of relative absence of RAS pathway mutations in 24 *TCF3-PBX1*-positive ALL samples. The latter analysis included *KRAS* exon 1, *NRAS* exons 1 and 2, *FLT3* exons 14 and 20, *PTPN11* exons 3 and 13 and was conducted as previously described^[@R63]^.

Multiplex Ligation-dependent Probe Amplification {#S22}
------------------------------------------------

Detection of genomic aberrations in B cell differentiation-associated and other genes frequently deleted in ALL (*PAX5*, *IKZF1*, *ETV6*, *RB1*, *BTG1*, *EBF1*, *CDKN2A, CDKN2B*, and *P2RY8-CRLF2*) were investigated by the Multiplex Ligation-dependent Probe Amplification (MLPA) assay SALSA p335 kit (MRC-Holland) using 125 ng of genomic DNA. The assays were performed according to the manufacturer's protocol as previously described^[@R64]^. An intensity ratio between 0.75 and 1.3 was considered to represent a normal copy number, a ratio between 0.25 and 0.75 a monoallelic deletion, and a ratio \<0.25 a biallelic deletion.

Bioinformatic analysis {#S23}
----------------------

### DNA data processing {#S24}

DNA reads were aligned to the human reference genome hg19 (downloaded from the UCSC Genome browser) using Elandv2^[@R65]^ (mate-pairs) and BWA^[@R66]^ (paired-ends). For xenograft samples, the human DNA reads were deconvoluted after mapping to a combined reference consisting of human hg19 and mouse mm9.

### Structural variant detection {#S25}

Structural variants (SVs) were detected using DELLY^[@R67]^ and BIC-seq^[@R68]^ (DNA data) and TopHat2^[@R69]^/deFuse^[@R70]^ (RNA data).

### SNV detection {#S26}

Somatic protein-changing SNVs were detected using established pipelines incorporating GATK^[@R71]^, MuTect^[@R72]^, pibase^[@R73]^, Picard, SAMtools^[@R74]^ and VarScan2^[@R75]^.

### Indel detection {#S27}

Somatic indels in coding regions were detected using SAMtools followed by Dindel^[@R76]^.

### Transcriptome data analysis {#S28}

RNA reads were aligned to hg19 using BWA and SAMtools and used for integrated data analysis. For xenograft samples, the human RNA reads were deconvoluted after mapping to a combined reference consisting of human hg19 and mouse mm9. Mapped reads were annotated using Ensembl v.70. Gene expression levels were quantified in reads per kilobase of exon model per million mapped reads (RPKM)^[@R77]^. RPKM calculation and differential gene expression (DGE) analysis was performed using the R package edgeR^[@R78]^. To identify DGE between ALL subtypes, and between leukemia and remission the following set-up was performed: *TCF3-PBX1* vs. *TCF3-HLF* (comparison 1), *TCF3-PBX1* vs. remission (comparison 2), *TCF3-HLF* vs. remission (comparison 3). The results were filtered by fold change (FC, \|log~2~(FC)\| \>= 1) and false discovery rate (FDR, FDR \<= 0.001). The final list of 401 genes was created by combining the intersection between comparison 1 and comparison 2 as well as between comparison 1 and comparison 3. The functional analyses of gene lists were done using Gene Set Enrichment Analysis (GSEA)^[@R59]^ and the Genomatix genome analyzer (v. 3.00801; Genomatix Software GmbH). The GeneRanker tool in Genomatix was used to test for enriched gene sets, which were based on gene-tissue annotations obtained by text mining^[@R60]^. For GSEA, protein-coding genes were filtered by a minimum expression of 1 RPKM in at least four samples among the primary pre-B cell ALLs. The remaining 11315 genes were tested for DGE between the ALL subtypes using edgeR. The provided FDR and fold-change values were used to obtain a ranking score to measure the degree of differential expression between the ALL subtype. A pre-ranked classic GSEA was performed using the ranking score, a gene set permutation and a FDR ≤ 0.02. The analysis included gene sets for hematopoietic stages^[@R31]^ and signatures from MsigDB^[@R59]^ pathways (C2): KEGG, BIOCARTA, REACTOME; curated oncogenic signatures (C6); human immunologic signatures (C7).

### In silico transcription factor binding site (TFBS) analysis {#S29}

TFBS in promoter regions of genes (2 kbp upstream region) corresponding to the specific transcriptome signatures of *TCF3-PBX1*- and *TCF3-HLF*-positive ALL, respectively, were analyzed using the Genomatix Genome Analyzer (v3.10124). Based on a matrix of known TFBS motifs, the software tool predicted TFBSs in the investigated promoters and compared their frequency against 1) the background of TFBSs in the promoter regions of all known protein-coding genes in the Ensembl database (v.70, 22864 genes) and 2) the background of TFBSs in the whole genome. A Z-score was calculated based on the TFBS frequency in the investigated promoters and the expected frequency and standard deviation were estimated from the background^[@R79]^. The resulting lists were filtered by the Z-scores based on the two backgrounds ( \|genomic Z-score\| ≥ 2 , promoter Z-score ≥ 2 ). TFBSs overrepresented in genes up-regulated in both *TCF3-PBX1*- and *TCF3-HLF*-positive ALL were filered out, to retain only TFBS specifically enriched in the respective subtypes.

### Integrated data analysis {#S30}

SNVs and indels were orthogonally validated by integrating genome, exome, and transcriptome data of patients and xenografts and further confirmed by Sanger sequencing. SVs were validated by integrating whole genome paired-end and mate-pair data and whole transcriptome data and finally by Sanger sequencing. Ensembl v.70 and ANNOVAR^[@R80]^ were used to annotate the variants. Silent variants and known germline variants in the 1000 Genomes Project^[@R81]^ population data, in 136 North German healthy controls (publicly available through GrabBlur^[@R82]^), or in the International Cancer Genome Consortium's internal healthy controls were eliminated. All final somatic non synonymous variants were inspected using IGV^[@R83]^.

Preclinical characterization {#S31}
----------------------------

### Xenograft model {#S32}

Animal experiments were approved by the veterinary office of the Canton of Zurich, Switzerland. Approval for experiments with human samples in the mouse xenograft model was obtained from the ethics commission of the Canton Zurich (approval number 2014-0383). In brief, primary ALL cells were recovered from cryopreserved samples and transplanted intrafemorally to NSG mice as previously described^[@R36]^. Mice were between 5 to 10 weeks old, both males and females were randomly used. Leukemia progression was monitored by flow cytometry with rat anti-mouse CD45 (eFluor®450, Clone 30-F11, REF 48-451-82, eBioscience), mouse anti-human CD45 (AlexaFlour647, Clone HI30, REF 304018, BioLegend), and mouse anti-human CD19 (PE, Clone HIB19, REF 302208, BioLegend). ALL cells recovered from spleens of NSG mice were used for molecular characterization in *in vitro* and *in vivo* experiments.

### Immunophenotyping {#S33}

Immunophenotyping of patient and xenograft-amplified human ALL cells after recovery from the spleen was performed as described before^[@R84]^. All included xenograft samples consisted of at least 95% human leukemic cells.

### Cell culture {#S34}

Human hTERT immortalized primary bone marrow mesenchymal stromal cells (MSC; provided by D. Campana, St. Jude Children's Research Hospital, Memphis, TN) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS h.i.); L-glutamine (2 mM), penicilline/streptomycin (P/S; 100 IU/ml) and hydrocortisone (1 μM). Xenograft-amplified human ALL cells were co-cultured on MSC in AIM V medium (Gibco by Life Technologies) at a ratio of 10:1. All cultured cells were kept in the incubator at 37°C, 5% CO~2~. For cryopreservation, cells were frozen in FBS h.i. with 10% dimethylsulfoxide and subsequently stored in liquid nitrogen.

### Cell viability assay {#S35}

MSCs were seeded in 24-well plates at a number of 50,000 cells per well in RPMI 1640 medium (10% FBS h.i.). After 24 hours primary ALL cells were thawed and seeded as suspension culture alone or in co-culture with MSCs at a number of 400,000 cells per well in AIM-V medium. Three days later, ALL cells were collected from monoculture or co-culture by scraping and stained with 7-AAD (BD Pharmingen). Cell viability (7-AAD negative population) was measured by FACS using counting beads (SPHERO Accu Count Blanc Particles, Spherotech Inc.) for cell counts normalization. Viabilities shown are average viabilities of duplicate wells (normalized to input) and standard deviations.

### Cell cycle assay {#S36}

MSCs were seeded in 96-well tissue culture plates at a concentration of 10,000 cells per well in 100 μL AIM-V medium. After 24 hours ALL cells were added at a concentration of 100,000 cells per well in 90 μL AIM-V. The Click-iTEdU Alexa Fluor 488 Flow Cytometry Assay Kit (Life Technologies) in combination with propidium iodide was used to measure proliferation and to identify the different phases of the cell cycle on days 1 and 3. Co-cultured cells were incubated with EdU (10 μM) for 20 hours before cell cycle read-out with flow cytometry. The cell cycle assay was performed in triplicates and at least two independent experiments were performed for each sample. Similar variances were obtained between the groups that were statistically compared.

### In vitro drug screening and automated microscopy {#S37}

MSCs were seeded in 384-well plates at a concentration of 2,500 cells per well in 30 μL AIM-V medium. After 24 hours, ALL cells were added at a concentration of 25,000 to 30,000 cells per well in 27.5 μL AIM-V. Drugs were added as single agents after additional 24 hours using the pipetting robot epMotion 5070 (Eppendorf). Drug response was normalized to ALL cells treated with the drug vehicle alone. Experiments were performed in duplicates in five different dilutions (1, 10, 100, 1,000 and 10,000 nM). For two samples comparable results were obtained in two independent drug screening experiments. After 72 or 96 hours of drug incubation, cells were stained using the CyQUANT direct cell proliferation assay (Life technologies). 20 μL staining mix (AIM V medium, CyQUANT (1:300), repressor (1:20)) was added into each well followed by an incubation time of 1 hour at 37°C, 5 % CO2. Subsequently, automated imaging was performed using the ImageXpress Micro microscope (Molecular Devices) equipped with a CoolSNAP HQ camera (Photometrics) and a 10x plan fluor objective with 0.3 NA (Nikon). Nine images were taken per well, covering 50% of each well and captured employing the MetaXpress software (Molecular Devices). Images were processed using CellProfiler software (Broad Institute, Cambridge, MA). Cells were classified and counted using the Advanced Cell Classifier software. This software uses random forest classification to assign ALL cells properly.

### Western blot {#S38}

Whole cell extracts were prepared from 1 × 10^6^ cells using radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-Cl pH 7.5, 150 mMNaCl, 1% NP-40, 1 mM EDTA pH 8.0, 0.1% SDS) supplemented with Complete mini protease inhibitor cocktail (Roche Life Science) for 20 minutes on ice, sonicated as necessary, and diluted with SDS loading buffer (250 mM Tris pH 6.8, 4% SDS, 0.02% bromophenol blue, 40% glycerol, 4% (v/v) β-mercaptoethanol). After SDS-PAGE, proteins were blotted onto nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk and incubated with primary Bcl-2 (Clone 124; Dako) and tubulin antibodies diluted 1:1,000 in milk. Horseradish peroxidase-labeled anti-mouse antibodies were used for signal detection with chemiluminescence substrate and direct scanning.

### In vivo experiments {#S39}

ALL cells were recovered from cryopreserved xenograft samples, and per thawed sample 12 to 16 mice were transplanted with 1,000,000 cells per mouse. After three days, randomized cohorts were treated with 100 mg/kg of ABT-199 (ABBVIE) or vehicle control with 6 to 8 mice per treatment arm^[@R85]^. ABT-199 or vehicle control were administered orally daily for two weeks. Mice of the ABT-199 group transplanted with sample 7a were additionally treated with a second block (100 mg/kg of ABT-199 for 14 days) starting at day 66, when the frequency of circulating leukemia cells started to increase again. Follow-up of circulating leukemia cells was performed every seven days by flow cytometry with rat anti-mouse CD45, mouse anti-human CD45, and mouse anti-human CD19; frequency of leukemia cells as ratio of mCD45^-^hCD45^+^ hCD19^+^ count to total lymphocytes. The investigator was blinded to the group allocation during the assessment of outcome. To evaluate the ability of ABT-199 to decrease tumor burden, four mice in the control group were treated when the frequency of leukemia cells in the peripheral blood was equal or higher than 50%. Follow-up of circulating leukemia cells was performed every four to seven days. *In vivo* experiments were terminated when the frequency of circulating leukemia cells reached 50% or earlier if the mice showed abnormal behavior. One *in vivo* experiment was performed per each sample.

Statistical analysis {#S40}
--------------------

Differences in the distribution of categorical variables among patient subsets were analyzed using Fisher's exact or chi-squared test. Comparisons of continuous variables between groups were performed by t-test or Mann-Whitney *U* test.

Drug responses were evaluated by fitting DMSO-normalized response data with the four-parameter log-logistic function of the form: $$f\left( x \right) = \,\mathit{base}\, + \,\frac{E_{\mathit{\max}} - \mathit{base}}{\mathit{1}\, + \left( x_{\mathit{1} \slash \mathit{2}}\slash x \right)\mathit{Coeff}}$$ as implemented in the drc package of R (version 2.3-96). Outliers were detected and removed prior to curve-fitting using Bayesian change point analysis^[@R25]^ (R package bcp, version 3.0.1). Non-convergent cases (e.g., drugs with no activity) were identified based on linear fit parameters. Hierarchical clustering was performed to group patients according to their drug-response profiles (R package gplots version 2.14.2). Drugs with differential activity in patients with *TCF3-PBX1*- compared to *TCF3-HLF*-positive ALL were identified using a t-test (p-value \<= 0.05). In *in vivo* experiments, 25% of circulating leukemia cells or termination of the experiment if 25% of leukemia was not reached were considered as an event in the Kaplan-Meier analysis. For sample 9a, 50% was used because of the rapid engraftment. Differences in the survival of mice receiving ABT-199 or vehicle control were determined by the Mantel-Cox test and verified by the Gehan-Breslow-Wilcoxon test.
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![Genetic lesions identified in pediatric *TCF3-HLF*- and *TCF3-PBX1*-positive ALL\
**(a)** Breakpoints in *TCF3*, *PBX1* and *HLF* cluster in genomic hotspot regions. Boxes correspond to exonic regions; arcs represent fusions in patient samples. **(b)** *TCF3* breakpoints cluster in two *TCF3* intronic regions: between exons 16 and 17 (type 1) and between exons 15 and 16 (type 2). On the transcript level, type 1 translocations join *TCF3* exon 16 to *HLF* exon 4, including inserted non-template and intronic sequences and new splice acceptor sites (patients 8 and 9). Type 2 translocations occur downstream of exon 15 and exclude *TCF3* exon 16 from the fusion transcript (patients 6, 7 and 11). **(c)** Absence of overlapping somatic structural and nucleotide variations between the cohorts. *TCF3-HLF*-positive ALL is characterized by mutually exclusive *PAX5, BTG1 and VPREB1* deletions and nonsynonymous nucleotide variations in *TCF3* (p.Asp561Val, "D561V" in patient 8 and p.Ser467Gly in patient 13 of the validation cohort, the latter not included here). Subclonal RAS pathway mutations are exclusively detected in *HLF*-, but not in *PBX1*-fused cases. **(d)** Models of wild-type and mutant TCF3 based on the crystal structure of TCF3 in complex with the transcription factors SCL, LMO2 and LDB1 bound to DNA.^[@R58]^ Upon LMO2 binding, bonds are formed between TCF3 and SCL, including a hydrogen bond (dashed line) between D561 and R230 reducing the DNA binding capacity of the complex. Inset: D561V introduces a hydrophobic valine residue close to polar residues that may interfere with hydrogen bonding, thus altering the DNA binding properties of the complex. (For details see Source file for [Figure 1](#F1){ref-type="fig"}.)](emss-64036-f0001){#F1}

![*TCF3-HLF* programs leukemia to a hybrid hematopoietic transcriptional state\
**(a)** Heatmap of the 401 differentially expressed genes between the two ALL subtypes (edgeR, \|log~2~(fold change)\| ≥ 1, FDR ≤ 0.001). **(b)** Enriched hematopoietic stages in *TCF3-HLF*-positive (orange) and *TCF3-PBX1*-positive (green) ALL. Stages shown include hematopoietic stem cells (HSC), common myeloid progenitors (CMP), lymphoid-specified progenitors (GMP and MEP), neutrophils (NEUTRO), monocytes (MONO), multilymphoid progenitor (MLP), early T cell precursors (ETP), pro-B cells (PROB), T cells (TCELL), and B cells (BCELL). Gene set enrichment analysis was carried out using Genomatix genome analyzer and Gene Set Enrichment Analysis (GSEA)^[@R59]^ (GSEA: FDR ≤ 0.02; genomatix genome analyzer: adjusted p-value ≤ 0.02). The source of the significant enriched gene sets is noted by the superscript: 1) curated gene sets of hematopoietic precursors^[@R31]^; 2) human immunologic gene signatures (MSigDB v4.0)^[@R32]^; 3) text mining-based tissue specific gene sets^[@R60]^. **(c)** Enrichment plot for the HSC signature^[@R31]^. **(d)** Components of the *TCF3-HLF*-positive ALL signature reveal functional annotation related to stem cells and their cellular location (Genomatix genome analyzer: p-value = 4.65 × 10^−4^, adjusted p-value \< 0.001). (For details see Source file for [Figure 2](#F2){ref-type="fig"}.)](emss-64036-f0002){#F2}

![The genomic landscape of *TCF3-HLF*- and *TCF3-PBX1*-positive ALL is preserved in patient-derived leukemia xenografts\
**(a)** Xenografts were established from cryopreserved patient samples at diagnosis (samples "a"), at follow-up with minimal residual disease (MRD, \<1 leukemic cell in 10,000 cells, samples "b") or from disease progression (samples "c") and subjected to whole exome and transcriptome sequencing as well as multiplex ligation-dependent probe amplification (MLPA). All available MRD samples from *TCF3-HLF*-positive cases were successfully engrafted. **(b)** Comparison of all transcriptionally expressed nucleotide variations and of selected recurrent deletions frequently found in pediatric ALL in corresponding patient (P) and xenograft (X) samples. Deletions and nucleotide variations are colored according to their frequency in the analyzed leukemic cell population. Deletion frequencies were calculated by integrating whole genome and whole exome sequencing data with MLPA data. Nucleotide variation frequencies were calculated by integrating whole genome, whole exome and transcriptome sequencing data. (For details see Source file for [Figure 3](#F3){ref-type="fig"}.)](emss-64036-f0003){#F3}

![Major components of the gene expression signature of *TCF3-HLF*- and *TCF3-PBX1*-positive ALL are conserved in patient-derived xenografts\
Hierarchical clustering of primary and patient derived xenograft (PDX) ALL samples based on the expression of the 401 genes of the signature defined with primary samples ([Fig. 2](#F2){ref-type="fig"}) shows that xenografts clearly group with their corresponding primary samples. (For details see Source file for [Figure 4](#F4){ref-type="fig"}.)](emss-64036-f0004){#F4}

![Drug activity profiling of *TCF3*-translocated leukemia reveals relevant differences in drug sensitivity\
**(a)** Unsupervised clustering based on the drug activity profile of 98 compounds (logIC~50~) separates the two subtypes. Fitted values are provided in the supplementary section (absolute IC~50~). Numbers identify the compounds shown in (c). **(b)** Principal component analysis of the response variables IC~50~, EC~50~, EC~90~ and AUC ([Supplementary Table 24](#SD3){ref-type="supplementary-material"}) show *TCF3-PBX1*-positive and *TCF3-HLF*-positive ALL in two distinct clusters. The separation of *TCF3-PBX1*-positive and *TCF3-HLF*-positive ALL is determined by responses to topoisomerases, BCL2 inhibitors, glucocorticoids and antimitotic agents, which correlate with the first three principal components. **(c)** Selection of drugs based on differences in sensitivity or resistance in *TCF3-PBX1*-positives and *TCF3-HLF*-positives. For comparison, the corresponding drug activity is indicated for 25 additional ALL samples tested on the same platform, including standard risk (SR, n=5), medium risk (MR, n=4), and high risk (HR, n=16) cases ([Supplementary Table 25](#SD3){ref-type="supplementary-material"}). Boxplots extend from the first to the third quartiles (hinges) of the response range for each compound. Whiskers correspond to values from the hinge to the lowest or highest values within 1.5x of the distance between the first and third quartiles, respectively. Drugs with differential activity include docetaxel, paclitaxel, vincristine, AT9283, barasertib, BI2536, torin-1, dasatinib, lestaurtinib and XL228 (p≤0.05). Drugs which are active across the patients include doxorubicin, idarubicin, mitoxantrone, bortezomib, panobinostat, NVP-AUY922, ABT-199 (venetoclax) and navitoclax. (For details see Source file for [Figure 5](#F5){ref-type="fig"}.)](emss-64036-f0005){#F5}

![The BCL2 antagonist ABT-199 (venetoclax) shows promising anti-leukemic activity in *TCF3-HLF*-positive xenografts\
**(a)** *In vitro* dose response curves normalized against DMSO treated controls. **(b)** Merged absolute RPKM values of xenografts derived from the same primary leukemia sample (upper panel) and western blot for BCL2 (lower panel) in patient-derived xenografts as indicated. **(c,d)** *In vivo* response to ABT-199 on *TCF3-HLF*-positive xenografts. Treatment (grey bar) with 100 mg kg-1 qd ABT-199 (magenta) or with vehicle control (turquoise) were administered orally for 14 days (6-8 mice per treatment arm). Two treatment courses were administrated to xenograft 7a. For survival analysis an event was defined when at least 25% of leukemic cells were detected by FACS (mCD45^−^hCD19^+^hCD45^+^) in the peripheral blood. Differences in the survival of mice receiving ABT-199 or vehicle control were determined by the Mantel-Cox test and verified by the Gehan-Breslow-Wilcoxon test.\
**(e)** Mice from the control arm of (c,d) were treated with ABT-199 when more than 50% of ALL cells were detected in the blood. Mean and SD are shown (n=4). (For details see Source file for [Figure 6](#F6){ref-type="fig"}.)](emss-64036-f0006){#F6}

[^1]: These authors jointly supervised this work.
